Remove Antibody Remove In-Vitro Remove Protein
article thumbnail

China’s NMPA clears Transcenta’s IND for solid tumour treatment

Pharmaceutical Technology

TST003 is a first-in-class Gremlin1 targeting humanised monoclonal antibody. In the syngeneic tumour model, the monoclonal antibody has also improved the checkpoint inhibitor’s anti-tumour activity. In the syngeneic tumour model, the monoclonal antibody has also improved the checkpoint inhibitor’s anti-tumour activity.

Antibody 242
article thumbnail

Researchers Discover Genetic Errors and Rogue Antibodies in Cases of Severe COVID-19 Infection

XTalks

The research shows that the activity of the immune messenger type 1 interferon (IFN) protein is diminished, either by genetic mutations or an autoimmune attack by neutralizing antibodies against it, in a subset of COVID-19 patients. Related: Low T Cell Counts Observed in COVID-19 Patients. Mutational Errors in COVID-19 Patients.

Antibody 135
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

New method identifies antibody-like proteins with diagnostic and therapeutic potential for SARS-CoV-2

Scienmag

Antibody-like proteins that capture and neutralize SARS-CoV-2 Scientists have used a new high-speed, in vitro selection method to isolate 9 antibody-like proteins (ALPs) that bind to the SARS-CoV-2 virus – 4 of which also exhibited neutralizing activity – within 4 days, according to a new study.

Protein 53
article thumbnail

Biologic Therapeutics Development, Part 1: Definition and Distinct Characteristics

Camargo

Recombinant therapeutic proteins. Fusion proteins. Monoclonal antibodies (mAbs). In vitro binding assays and functional tests might be required to identify the test material which is pharmacologically active , and a potency assay is required due to the complexity and heterogeneity of biologics. Growth factors.

article thumbnail

How Nanobodies from Cormac the Llama Could Prevent COVID-19 Infection

XTalks

Researchers at the National Institutes of Health (NIH) in the US have isolated small antibodies called “nanobodies” from a llama named Cormac that can block the SARS-CoV-2 coronavirus. Nanobodies are about a quarter of the size, and approximately one tenth of the weight, of a typical human antibody. TJ” Esparza, BS, and David L.

Antibody 105
article thumbnail

A protein-based COVID-19 vaccine that mimics the shape of the virus

The Pharma Data

Now, researchers reporting in ACS Central Science have immunized mice with nanoparticles that mimic SARS-CoV-2 by displaying multiple copies of the receptor binding domain (RBD) antigen, showing that the vaccine triggers robust antibody and T cell responses. Although the first vaccines to receive Emergency Use Authorization by the U.S.

Protein 52
article thumbnail

Roche launches new quantitative antibody test to measure SARS-CoV-2 antibodies, to support the evaluation of vaccines

The Pharma Data

The new Elecsys Anti-SARS-CoV-2 S test can quantitatively measure the level of antibodies against SARS-CoV-2 in patients who have been exposed to the virus. The test targets antibodies against the spike protein. The majority of current candidate vaccines aim to induce an antibody response against the spike protein. “As